Tubulis
About Tubulis
Reimagining AntibodyDrug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and will
Recent News
STAT+: Gilead to Buy Cancer Biotech Tubulis for More than $3 Billion
Kymera Therapeutics Reports Gilead’s Option Exercise to License KT-200, a CDK2 Molecular Glue Degrader
Gilead to Acquire Germany's Tubulis for Up to $5 B, Boosting ADC Portfolio
HTGF: Where Public Mandate Meets Venture Discipline
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
TSMC Posts 35% Jump in Q1 Revenue
